(Q37334945)

English

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib

scientific article published on 16 July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib (English)

1 reference

Europe PubMed Central

19 August 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ingvild Mikkola

object named as

Ingvild Mikkola

7

0 references

Andreas Hochhaus

object named as

Andreas Hochhaus

10

0 references

Dietger Niederwieser

9

object named as

Dietger Niederwieser

1 reference

Europe PubMed Central

19 August 2017

author name string

Thomas Ernst

1

1 reference

Europe PubMed Central

19 August 2017

Franz X Gruber

2

1 reference

Europe PubMed Central

19 August 2017

Oliver Pelz-Ackermann

3

1 reference

Europe PubMed Central

19 August 2017

Jacqueline Maier

4

1 reference

Europe PubMed Central

19 August 2017

Markus Pfirrmann

5

1 reference

Europe PubMed Central

19 August 2017

Martin C Müller

6

1 reference

Europe PubMed Central

19 August 2017

Kimmo Porkka

8

1 reference

Europe PubMed Central

19 August 2017

Thoralf Lange

11

1 reference

Europe PubMed Central

19 August 2017

publication date

16 July 2009

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

94

1 reference

Europe PubMed Central

19 August 2017

9

1 reference

Europe PubMed Central

19 August 2017

1227-1235

1 reference

Europe PubMed Central

19 August 2017

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Chronic myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Resistance to targeted therapy in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

6 September 2017

Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

28 September 2017

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

26 June 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

2 September 2018

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

20 October 2018

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738714

3 December 2018

Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

1 reference

https://pubmed.ncbi.nlm.nih.gov/19608684

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19608684

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19608684

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19608684

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal Residual Disease after Bone Marrow Transplant for Chronic Myeloid Leukaemia Detected by the Polymerase Chain Reaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/19608684

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2009.006981

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37334945&oldid=2165196671"